FDA-approved 4 mg naloxone hydrochloride nasal spray for emergency treatment of opioid overdose.
Emergent BioSolutions
American biopharmaceutical company developing vaccines and therapeutics in Gaithersburg, MD.
Founded
1998American biopharmaceutical company developing vaccines and therapeutics in Gaithersburg, MD.
Emergent BioSolutions Inc., founded on September 5, 1998, by Fuad El-Hibri, is a biopharmaceutical company headquartered in Gaithersburg, Maryland. The company's core mission is to provide preparedness and response solutions for public health threats (PHTs), including chemical, biological, radiological, nuclear, and explosive threats, as well as emerging infectious diseases and public health crises. Emergent BioSolutions offers products such as the ACAM2000 smallpox vaccine and Anthrasil, among others, focusing on acute, emergency, and community care.
Notable affiliated individuals include interim CEO Haywood Miller. The company is publicly traded on the NYSE under the ticker EBS and is a component of the Russell 2000 index. Key achievements include the development and provision of critical vaccines and therapeutics that address significant public health threats. Emergent BioSolutions has made a substantial impact on public health preparedness and response, contributing to national and global health security.
Companies similar to Emergent BioSolutions include IBT Vaccines, Novavax, Emergo Therapeutics and Moderna.
Emergent BioSolutions was founded in 1998.
Emergent BioSolutions' headquarters is located in Gaithersburg, MD, US.
As of Nov 14, 2022, Emergent BioSolutions has disclosed funding of $36.5M (USD). Undisclosed round amounts are excluded.
Emergent BioSolutions has 2,500 employees as of Feb 6, 2024.
modernatx.com